Gentronix has launched its early genotoxicity screening assay BlueScreen HC. This cell-based product enables accurate and reliable early identification of compounds likely to induce genotoxic stress and damage. This helps reduce attrition rates in drug discovery and allows the prioritisation of compounds for further development in the R&D pipeline.
BlueScreen HC is a human cell-based reporter assay which requires only low milligram quantities of sample compounds. Providing a simple and effective alternative to fluorescence reporter systems the new Bluescreen HC assay monitors the expression of the P53 linked GADD45a gene, upregulated in response to genotoxic stress. The assay produces a flash luminescent output through the use of the Gaussia luciferase reporter gene.
For ease and speed of use, the BlueScreen HC assay is designed for 96-well microplates, enabling four compounds to be screened in multiple dilutions per plate. Additionally, the assay can be performed with ‘S9’ incubation for the detection of progenotoxins requiring metabolic activation. Available in a kit format, or through Gentronix’s screening service with a turnaround time of just two weeks, the BlueScreen HC assay provides full flexibility of use for drug discovery researchers.
Date: March 26, 2010
Source: Gentronix
